S-B. Kim - Asan Med Ctr, Dept Oncol, Seoul, South Korea

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 95 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

J. Ajani,F. El Hajbi, D. Cunningham, M. Alsina, P. Thuss-Patience, G. V. Scagliotti,M. Van den Eynde,S-b. Kim, K. Kato, L. Shen,L. Li, N. Ding,

ESMO Openno. 1 (2024): 102202-102202

引用0浏览0WOS引用

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

A T C Chan,V H F Lee,R-L Hong,M-J Ahn,W Q Chong,S-B Kim,G F Ho, P B Caguioa,N Ngamphaiboon,C Ho, M A S A Aziz,Q S Ng,

Annals of Oncology（2023）

引用15浏览0WOS引用

1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy

A.N. Starodub,S-B. Kim, D. Davar, J. Powderly, A.G. Hill, O. Yeku, N. Gabrail, C. Krapp, S. Pihl, M. Chen, S. Slavsky, D. Torrejon Castro,

Annals of Oncology (2023): S628-S628

引用0浏览0引用

941P Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI

S.Y. Jang,Y-G. Lee, S.H. Chun,J.H. Park, K.U. Park,H. Chang,K-W. Lee, H.R. Kim,S-H. Shin, H.J. An,K-E. Lee, I.G. Hwang,

Annals of Oncology (2023): S591-S591

引用0浏览0引用

4MO Homologous recombination (HR) status of platinum-responsive advanced triple-negative breast cancers (aTNBC) treated with olaparib as maintenance therapy

T.J.Y. Tan, S. Sammons, J.L. Fink, W.S. Ong, B. Jaradi, P. Waring, Y.S.J. Chan, X.P. Lee, B.Y. Lim,J.C. Brady,A. Nixon, T.A. Traina,

ESMO Open（2023）

引用0浏览0引用

187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer

C-C. Lin,T.M. Kim, P. Desai, K.H. Lee, Y-H. Feng, N. Ngamphaiboon,S-B. Kim,M-H. Yang, J. Muzaffar, B. Chmielowski,P.L. Swiecicki, S.E. Bowyer,

Immuno-Oncology and Technology (2022): 100299-100299

引用0浏览0引用

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life

E Van Cutsem,K Kato,J Ajani,L Shen,T Xia,N Ding,L Zhan,G Barnes,S-B Kim

ESMO Open（2022）

引用7浏览0WOS引用

Pathologic complete response, long-term outcomes, and recurrence patterns in HER2-low vs HER2-zero breast cancer after neoadjuvant chemotherapy

S. Kang, S. H. Lee, H. J. Lee,H. Jeong,J-H. Jeong, J. E. Kim,J-H. Ahn, K. H. Jung, G. Gong,H. H. Kim, S. Lee, J. Lee,

SSRN Electronic Journalno. 7 (2022): S624-S624

引用0浏览0WOS引用

Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in …

F Marmé,M Martin, M Untch, HR Bonnefoi,SB Kim,HD Bear, N Mc Carthy

user-6073b1344c775e0497f43bf9（2021）

引用2浏览0引用

Results Of Keynote-122: A Phase Iii Study Of Pembrolizumab (Pembro) Monotherapy Vs Chemotherapy (Chemo) For Platinum-Pretreated, Recurrent Or Metastatic (R/M) Nasopharyngeal Carcinoma (Npc)

A. T. Chan, V. H. F. Lee,R-L. Hong,M-J. Ahn, W. Q. Chong,S-B. Kim,H. Gwo Fuang, P. B. Caguioa,N. Ngamphaiboon,C. Ho,M. A. S. Abdul Aziz,Q. S. Ng,

ANNALS OF ONCOLOGY（2021）

引用28浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn